IE832770L - Acridanone derivative. - Google Patents

Acridanone derivative.

Info

Publication number
IE832770L
IE832770L IE832770A IE277083A IE832770L IE 832770 L IE832770 L IE 832770L IE 832770 A IE832770 A IE 832770A IE 277083 A IE277083 A IE 277083A IE 832770 L IE832770 L IE 832770L
Authority
IE
Ireland
Prior art keywords
signifies
see diagramm
lower alkyl
group
hydrogen
Prior art date
Application number
IE832770A
Other versions
IE56311B1 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IE832770L publication Critical patent/IE832770L/en
Publication of IE56311B1 publication Critical patent/IE56311B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/06Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • C07D219/10Nitrogen atoms attached in position 9
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00Liquid crystal materials
    • C09K19/04Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06Non-steroidal liquid crystal compounds
    • C09K19/08Non-steroidal liquid crystal compounds containing at least two non-condensed rings
    • C09K19/10Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing at least two benzene rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

For the Contracting States BE CH DE FR GB IT LI LU NL SE 1. Acridanone derivatives of the general formula see diagramm : EP0110298,P20,F1 wherein the dotted line signifies an optional bond, R**1 signifies hydrogen, halogen or nitro, R**2 signifies hydrogen or lower alkyl, one of the symbols R**3 and R**4 signifies hydrogen or lower alkyl and the other together with R signifies an additional bond, A signifies lower alkylene, R**5 signifies a 5-membered, nitrogen-containig, optionally lower alkyl-substituted aromatic heterocycle, amino or a group see diagramm : EP0110298,P20,F2 or see diagramm : EP0110298,P20,F3 the symbol see diagramm : EP0110298,P20,F4 signifies a 5- or 6-membered, optionally lower-alkyl substituted saturated heterocycle which can contain as a ring member an oxygen or sulphur atom or the group >NH ou >N(B)n -A**1-R**6, B signifies the group -CO-, -COO- or -SO2 -, n signifies the number 0 or 1, A**1 signifies lower alkylene, R**6 signifies hydrogen, amino, lower alkylamino or di(lower alkyl)amino and R**7 signifies hydrogen or lower alkyl, and the residues denoted as lower contain 1 to 7 carbon atoms, and pharmaceutically acceptable acid addition salts thereof. For the Contracting State AT 1. A process for the manufacture of acridanone derivatives of the general formula see diagramm : EP0110298,P22,F1 wherein the dotted line signifies an optional bond, R**1 signifies hydrogen, halogen or nitro, R**2 signifies hydrogen or lower alkyl, one of the symbols R**3 and R**4 signifies hydrogen or lower alkyl and the other together with R signifies an additional bond, A signifies lower alkylene, R**5 signifies a 5-membered, nitrogen-containing, optionally lower alkyl-substituted aromatic heterocycle, amino or a group see diagramm : EP0110298,P23,F2 or see diagramm : EP0110298,P23,F3 the symbol see diagramm : EP0110298,P23,F4 signifies a 5- or 6-membered, optionally lower-alkyl substituted saturated heterocycle which can contain as a ring member an oxygen or sulphur atom or the group >NH ou >N(B)n -A**1-R**6, B signifies the group -CO-, -COO- or -SO2 -, n signifies the number 0 or 1, A**1 signifies lower alkylene, R**6 signifies hydrogen, amino, lower alkylamino or di(lower alkyl)amino and R**7 signifies hydrogen or lower alkyl, and the residues denoted as lower contains 1 to 7 carbon atoms, and pharmaceutically acceptable acid addition salts thereof, characterized by a) cyclizing a compound of the general formula see diagramm : EP0110298,P23,F5 wherein one of the symbols R**31 and R**41 signifies hydrogen or lower alkyl and the other signifies hydrogen, R**42 signifies hydrogen or lower alkyl, R**51 signifies a residue R**5, but does not contain a primary or secondary basic amino group, and X' signifies a leaving group, and R**1, R**2 and R**5 have the above significance, b) reacting a compound of the general formula see diagramm : EP0110298,P23,F6 wherein A, R**1, R**42 and R**51 have the above significance, with a compound of the general formula see diagramm : EP0110298,P23,F7 wherein X" signifies a leaving group and the dotted line and R**2 have the above significance, or c) reacting a compound of the general formula see diagramm : EP0110298,P23,F8 wherein Y(anion) signifies an anion and X signifies a leaving group, and A, R**1 and R**51 have the above significance, with a compound of the general formula see diagramm : EP0110298,P23,F9 wherein the dotted line, R, R**2, R**3 and R**4 have the above significance, or d) cleaving off the N-protecting group in a compound of the general formula see diagramm : EP0110298,P24,F10 wherein R**8 signifies a residue R**5 which contains a primary or secondary basic amino group blocked by a N-protecting group and the dotted line, R, R**1, R**2, R**3 and R**4 have the above significance, and e) if desired, converting a compound of formula I obtained into a pharmaceutically acceptable acid addition salt. [EP0110298A1]
IE2770/83A 1982-11-26 1983-11-25 Acridanone derivatives IE56311B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH689682 1982-11-26

Publications (2)

Publication Number Publication Date
IE832770L true IE832770L (en) 1984-05-26
IE56311B1 IE56311B1 (en) 1991-06-19

Family

ID=4316762

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2770/83A IE56311B1 (en) 1982-11-26 1983-11-25 Acridanone derivatives

Country Status (24)

Country Link
EP (1) EP0110298B1 (en)
JP (1) JPS59108783A (en)
KR (1) KR840006653A (en)
AR (1) AR240934A1 (en)
AT (1) ATE34749T1 (en)
AU (1) AU565078B2 (en)
BR (1) BR8306513A (en)
CA (1) CA1258854A (en)
CS (1) CS235991B2 (en)
DE (1) DE3376832D1 (en)
DK (1) DK542383D0 (en)
DO (1) DOP1983004180A (en)
ES (3) ES527552A0 (en)
FI (1) FI79847C (en)
HU (1) HU192829B (en)
IE (1) IE56311B1 (en)
IL (1) IL70273A (en)
MC (1) MC1556A1 (en)
NO (1) NO160139C (en)
NZ (1) NZ206317A (en)
PH (1) PH19364A (en)
PT (1) PT77730B (en)
ZA (1) ZA838639B (en)
ZW (1) ZW23783A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2036198C1 (en) * 1993-04-01 1995-05-27 Товарищество с ограниченной ответственностью "Полисан" N-METHYL- N- (α-D- GLUCOPYRANOSYL) -AMMONIUM -2-(ACRIDONE -9-ONE -10-YL) -ACETATE (CYCLOFERON) SHOWING INTERFEROGENIC, ANTIVIRAL AMONG THEM ANTI-HIV, ANTIPARASITIC, ANTIPROMOTER AND RADIOPROTECTIVE ACTIVITIES
US7829578B1 (en) 2005-12-12 2010-11-09 Oregon Health & Science University Aromatic ketones and uses thereof
WO2008064011A1 (en) 2006-11-13 2008-05-29 The Government Of The U.S. Of America As Represented By The Department Of Veterans Affairs Acridone compounds
US8598354B2 (en) 2008-12-05 2013-12-03 University Of South Florida Compounds having antiparasitic or anti-infectious activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1068595A (en) * 1964-06-08 1967-05-10 Gevaert Photo Prod Nv Colour photographic process
DE1811409A1 (en) * 1968-11-28 1970-06-18 Bayer Ag Preparations for combating insects, mites, rabbits and rodents

Also Published As

Publication number Publication date
ES8604213A1 (en) 1986-01-16
ES8504184A1 (en) 1985-04-16
KR840006653A (en) 1984-12-01
FI79847B (en) 1989-11-30
FI834321A (en) 1984-05-27
CS235991B2 (en) 1985-05-15
MC1556A1 (en) 1984-08-31
PT77730A (en) 1983-12-01
BR8306513A (en) 1984-07-03
IL70273A0 (en) 1984-02-29
PH19364A (en) 1986-04-02
ATE34749T1 (en) 1988-06-15
IL70273A (en) 1987-01-30
AR240934A2 (en) 1991-03-27
ES527552A0 (en) 1985-04-16
NO160139C (en) 1989-03-15
NZ206317A (en) 1987-06-30
DOP1983004180A (en) 1988-12-19
AU565078B2 (en) 1987-09-03
FI834321A0 (en) 1983-11-24
NO160139B (en) 1988-12-05
HU192829B (en) 1987-07-28
NO834344L (en) 1984-05-28
PT77730B (en) 1986-05-12
DK542383D0 (en) 1983-11-25
ZA838639B (en) 1984-07-25
ES534337A0 (en) 1986-01-16
EP0110298B1 (en) 1988-06-01
DE3376832D1 (en) 1988-07-07
ES534338A0 (en) 1985-06-01
CA1258854A (en) 1989-08-29
JPS59108783A (en) 1984-06-23
IE56311B1 (en) 1991-06-19
FI79847C (en) 1990-03-12
ES8505367A1 (en) 1985-06-01
AR240934A1 (en) 1991-03-27
ZW23783A1 (en) 1985-05-22
EP0110298A1 (en) 1984-06-13
AU2148883A (en) 1984-05-31

Similar Documents

Publication Publication Date Title
EP0313512A3 (en) Benzothiadiazoles and their use in processes and compositions against plant diseases
ES8402833A1 (en) Azolyl-methyl oxiranes, their preparation and use as medicaments and plant protecting agents.
ATE408597T1 (en) ALIPHATIC NITROGEN CONTAINING FIVE-MEMBED RING COMPOUNDS
NO180196C (en) Analogous Process for Preparation of Therapeutically Active Amino and Nitro Containing Tricyclic Compounds
DK264880A (en) PYRAZOLOQUINOLINES AND THEIR PREPARATION AND USE
IE832770L (en) Acridanone derivative.
GB1213172A (en) Dibenzothiazepine derivatives and production of the same
IL85725A (en) Imidazole derivatives,their manufacture and pharmaceutical compositions containing them
DE3161895D1 (en) 5-substituted-9-cyane-methylene-dithieno(3,4-b:4',3'-e) azepines, process for their preparation and pharmaceutical compositions containing them
GB1012619A (en) Improvements in or relating to dibenzocyclohepta-diene and -triene derivatives
ES8702877A1 (en) Benzoic acid derivatives and process for their preparation
TH434EX (en) 3,6,7,8-substrate-s-triazolo [4,3-b] Piridazine
ES271204A1 (en) Improvements in or relating to guanidine derivatives suitable for combating noxious organisms
EP0233287A4 (en) 1,4-thiazine derivatives, process for their preparation, and cardiotonics containing the same.